Gábor Szabó

Gábor Szabó

Auto-generated profile, based on publicly available information

Gábor Szabó

University Clinic and Outpatient Clinic for Cardiac Surgery, University Medicine Halle, Halle (Saale), Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
MFMina Farag
Mina Farag
DBDominika Badowski
Dominika Badowski
RKRonald Koschny
Ronald Koschny
GSGisela Skopp
Gisela Skopp
ABAndreas Brcic
Andreas Brcic
GSGabor B. Szabo
Gabor B. Szabo

1 March 2008 in Academic Radiology
Verified
Journal Article
Closed access
RURoland Unterhinninghofen
Roland Unterhinninghofen
SLSebastian Ley
Sebastian Ley
JLJulia Ley-Zaporozhan
Julia Ley-Zaporozhan
HTHendrik von Tengg-Kobligk
Hendrik von Tengg-Kobligk
MBMichael Bock
Michael Bock
RDRüdiger Dillmann
Rüdiger Dillmann

1 July 2003 in Surgery
Verified
Journal Article
Closed access
TATerézia B. Andrási
Terézia B. Andrási
PSPál Soós
Pál Soós
GBGellért Bakos
Gellért Bakos
NSNicole Stumpf
Nicole Stumpf
ABAnna Blazovics
Anna Blazovics
GSGábor Szabó
Gábor Szabó

22 February 2012
Verified
Book
Closed access
GSGábor Szabó
Gábor Szabó
Hier treffen Sie auf ein vielseitiges Sortiment an wissenschaftlicher Literatur und finden den richtigen Verleger für Ihr Fachbuch.

1 December 2004 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
GSG. Szabó
G. Szabó
LSL. Seres
L. Seres
PSP. Soós
P. Soós
CFC. Flechtenmacher
C. Flechtenmacher
ZZZsuzsanna Kinga Zsengeller
Zsuzsanna Kinga Zsengeller
SHS. Hagl
S. Hagl
Background: We investigated the effects of PARS inhibition on intestinal injury in a canine model of cardiopulmonary bypass (CPB). Methods: Twelve dogs underwent 90 minutes of hypothermic CPB. 6 dogs received 5 mg/kg PJ34, a selective PARP inhibitor during CPB, 6 vehicle-treated animals served as controls. Mesenteric blood flow (MBF) and mesenteric vascular resistance (MVR) were measured before and 60 minutes after weaning from CPB. Endothelium-dependent vasorelaxation to acetylcholine (ACH) and endothelium-independent vasorelaxation to sodium-nitroprussid (SNP) were expressed as percent change of MVR. In addition, mesenteric creatinkinase (CK) and lactate release were determined. Results: Baseline hemodynamics, MBF, response to ACH (- 41 ± 3 vs. - 55 ± 6 %) and SNP (- 60 ± 2 vs. - 56 ± 4 %) did not differ significantly between the groups. The response to ACH decreased significantly in the control group while it remained unchanged in the PJ34 group (- 29 ± 5 vs. - 46 ± 9 %, p < 0.05). The response to SNP did not change. Mesenteric CK release (325 ± 99 vs. 16 ± 10 U/l, p < 0.05) and lactate production (0.96 ± 0.17 vs. 0.4 ± 0.2 mmol/l, p < 0.05) were significantly lower in the PJ34 group. Conclusion: PARP inhibition prevents CPB-induced mesenteric endothelial dysfunction and tissue damage. 1 This study was presented at the 4th Joint Meeting of the German, Austrian, and Swiss Society for Thoracic and Cardiovascular Surgery, Hamburg, February 15 - 18, 2004

24 February 2009 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
KHKristof Hirschberg
Kristof Hirschberg
TGTímea Gombos
Tímea Gombos
EDEdit Dósa
Edit Dósa
ASAttila Somorjai
Attila Somorjai
ÁSÁgnes Szilágyi
Ágnes Szilágyi
LELászló Entz
László Entz